Maze Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule precision medicines for kidney and metabolic diseases using its proprietary Compass platform to identify disease-causing genetic variants. The company's lead programs target large patient populations with significant unmet medical needs: MZE829 addresses APOL1-mediated kidney disease in genetically predisposed patients, while MZE782 targets phenylketonuria and chronic kidney disease. Currently pre-revenue, the company funds operations through milestone and royalty payments from out-licensed programs and anticipates future revenue from the commercial sale of its internally developed candidates following regulatory approval.